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AbstrAct
background/Aim The rare mitochondrial DNA 
(mtDNA) variant m.8340G>A has been previously 
reported in the literature in a single, sporadic case 
of mitochondrial myopathy. In this report, we aim to 
investigate the case of a 39-year-old male patient with 
sensorineural deafness who presented to the eye clinic 
with nyctalopia, retinal pigmentary changes and bilateral 
cortical cataracts.
Methods The patient was examined clinically 
and investigated with autofluorescence, full-field 
electroretinography, electro-oculogram and dark 
adaptometry. Sequencing of the mitochondrial 
genome in blood and muscle tissue was followed by 
histochemical and biochemical analyses together with 
single fibre studies of a muscle biopsy to confirm a 
mitochondrial aetiology.
results Electrophysiology, colour testing and dark 
adaptometry showed significant photoreceptor 
dysfunction with macular involvement. Sequencing 
the complete mitochondrial genome revealed a 
rare mitochondrial tRNALys (MTTK) gene variant—
m.8340G>A—which was heteroplasmic in blood (11%) 
and skeletal muscle (65%) and cosegregated with 
cytochrome c oxidase-deficient fibres in single-fibre 
studies.
conclusion We confirm the pathogenicity of the 
rare mitochondrial m.8340G>A variant the basis of 
single-fibre segregation studies and its association 
with an expanded clinical phenotype. Our case expands 
the phenotypic spectrum of diseases associated with 
mitochondrial tRNA point mutations, highlighting the 
importance of considering a mitochondrial diagnosis 
in similar cases presenting to the eye clinic and the 
importance of further genetic testing if standard 
mutational analysis does not yield a result.
IntroductIon
Mitochondrial DNA (mtDNA) disease can be caused 
by mutations (single-nucleotide substitutions or 
large-scale rearrangements) that arise either in the 
mitochondrial genome (primary mtDNA disorders) 
or in nuclear genes whose protein products are inti-
mately linked to mtDNA maintenance, replication 
or repair.1 According to recent estimates, mtDNA 
mutations causing clinically manifesting disease 
affect 1 in 5000 individuals.2 To date, as many as 300 
distinct, disease-causing mutations within the mito-
chondrial genome have been characterised, and of 
these, the vast majority involve the genes coding the 
22 mitochondrial transfer RNA (mt-tRNA) mole-
cules.3 Furthermore, just three genes—MTTL1, 
MTTI and MTTK encoding mt-tRNALeu(UUR), mt-tR-
NAIle and mt-tRNALys, respectively—harbour over 
a third of all mt-tRNA mutations. Point mutations 
in mt-tRNA genes are thought to impair overall 
mitochondrial translation as a result of alterations 
to mt-tRNA secondary structure.1
Mt-tRNA mutations have been reported to cause 
a wide range of clinical disorders with consider-
able phenotypic heterogeneity, variable age of onset 
and disease severity.4 These differences, aside from 
presenting a diagnostic challenge, make the preva-
lence of pathogenic mitochondrial mutations difficult 
to ascertain. One of the factors contributing to the 
variable penetrance observed in many mtDNA-as-
sociated diseases is the phenomenon of hetero-
plasmy due to a multicopy mitochondrial genome. 
In patients with pathogenic mtDNA mutations, each 
cell contains both mutated and wild-type mitochon-
drial genomes, and as such the proportion (or ‘ratio’) 
of mutated to wild-type genomes in a given tissue 
contributes markedly to the age at onset, severity 
and extent of the phenotype. In most cases, mutation 
load within a specific tissue has to exceed a critical 
threshold level of mtDNA mutation level for manifest 
disease to be present, which can also contribute to a 
delay in making a diagnosis.1
Mt-DNA diseases can be broadly classified into 
multisystemic syndromes including maternally Inher-
ited diabetes and deafness (MIDD), neurogenic 
weakness, ataxia and retinitis pigmentosa, myoc-
lonic epilepsy and ragged-red fibres (MERRF) and 
mitochondrial encephalomyopathy, lactic acidosis 
and stroke-like episodes or isolated, organ-specific 
diseases such as myopathy (including ocular myop-
athy), sensorineural deafness, retinopathy or cardio-
myopathy.5 Ophthalmic manifestations are commonly 
seen in mitochondrial disorders and include bilateral 
optic neuropathy, progressive external ophthal-
moplegia and ptosis, pigmentary retinopathy and 
retro-chiasmal visual loss.6
More specifically, pathogenic mutations in the 
MTTK gene predominantly result in multisystemic 
disorders that affect the central nervous system 
including the MERRF syndrome.7 Jeppesen and 
colleagues recently described a patient with a 
heteroplasmic m.8340G>A MTTK variant mani-
festing as isolated myopathy.8 Here, we report a 
case of a 39-year-old man harbouring the identical 
mtDNA point mutation with an extended phenotype 
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Figure 1 Colour fundus photographs and fundus autofluorescence 
(AF). (A and b) Colour fundus photographs (Optos PLC, Dunfermline, 
Scotland, UK) showing bilateral posterior pole atrophic changes more 
pronounced in the left eye. (c and d) Autofluorescence showing 
grossly reduced signal in the peripapillary region in both eyes (arrows), 
encroaching on the central macula in the right eye with a temporal 
area of AF loss in the left eye. Both show areas of increased stippled 
autofluorescence signal representing disturbed affected retinal pigment 
epithelium (stars).
Figure 2 Goldmann visual fields showing paracentral scotomas in the 
right (A) field and centrocaecal scotoma in the left (b).
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of childhood epilepsy, migraines and sensorineural deafness 
who presented to eye clinic with night blindness and cataracts. 
Ophthalmic assessment revealed pigmentary retinopathy with rod 
and cone cell dysfunction.
PAtIent And Methods
case report
The patient was born to non-consanguineous Caucasian parents 
following an uncomplicated pregnancy with a normal delivery 
at term, but had episodes of febrile convulsions as a toddler. 
His development was otherwise normal with no significant 
psychomotor delay or learning difficulties. At 5 years of age he 
was diagnosed and treated for myoclonic epilepsy. He stopped 
treatment at the age of 15 years and has remained seizure free 
since. As a child, the patient was noted to be of short stature and 
was diagnosed with growth hormone deficiency for which he 
received growth hormone supplementation. His medical history 
was also relevant for recurrent migraines starting as a teenager, 
but with a decrease in severity and frequency over the last 20 
years. From the age of 20, he developed sensorineural hearing 
loss necessitating the use of hearing aids—a condition he had 
initially attributed to working as a drumming instructor. Family 
history of note includes: short stature (5 ft 1 in) in both parents 
and deafness in a maternal great-grandfather.
By 31 years, he had developed bilateral night blindness and 
photosensitivity with glare. At that time, he had not noted any 
gait disturbance or muscle weakness.
clinical findings
Clinical examination revealed short stature with normal muscle 
bulk. However, he had elbow contractures and a stiff spine. 
Power was normal in all muscle groups except mildly reduced 
(Medical Research Council grade 4+/5) in ankle eversion. 
Reflexes were brisk with no evidence of any ataxia.
Ocular examination revealed visual acuities of Right: 6/18 
and Left: 6/9 unaided. There was no evidence of ptosis or 
ophthalmoplegia. Intraocular pressure measurements were 
normal. Early cataracts were noted at first presentation, which 
progressed, requiring cataract surgery. Funduscopy revealed 
granular, pigmentary mottling affecting the macula accompanied 
by atrophic patches, with punctate light and dark pigmentation 
consistent with a ‘salt-and-pepper’ retinopathy. There was mild 
vascular attenuation but no intraretinal bone spicule pigmenta-
tion (figure 1A, B). Autofluorescence (Heidelberg Retina Angio-
graph, Heidelberg Engineering, Heidelberg, Germany) revealed 
a grossly reduced signal particularly affecting the maculae 
consistent with atrophy (figure 1C, D). Goldmann kinetic perim-
etry showed paracentral scotomas in the right visual field and 
centrocaecal scotoma in the left (figure 2). Dark adaptometry 
showed minimal cone adaptation and no dark adaptation after 
45 min. Colour contrast sensitivities revealed elevated tritan 
and protan thresholds in both eyes. Full-field electroretinog-
raphy (ERG) revealed reduced scotopic and photopic ampli-
tudes and increased implicit times demonstrating involvement 
of both photoreceptor systems, which showed similar results 
when repeated a year later. Electro-oculography (EOG) showed 
a reduction in light rise (left 109%; right 128%; table 1).
resuLts
Mitochondrial genetic studies
A peripheral blood leucocyte sample was screened for common 
mtDNA point mutations (m.3243A>G, m.8344A>G, 
m.8993T>G/C) and primary Leber Hereditary Optic Neuropathy 
mutations, but no causal variants were identified. Subsequently, 
sequencing of the complete mitochondrial genome (Ion Torrent 
next-generation sequencing) was undertaken to screen for novel 
or rare pathogenic mtDNA variants, revealing the m.8340G>A 
MTTK change at a low level of heteroplasmy (11% in blood). 
A skeletal muscle biopsy was taken to confirm a diagnosis of 
mitochondrial disease, revealing the m.8340G>A variant at an 
intermediate level of heteroplasmy (65% as determined by quan-
titative pyrosequencing).
Quantitative pyrosequencing of DNA samples obtained from 
the patient’s mother showed no evidence of the m.8340G>A 
mutation in buccal epithelia, urinary sediment or a blood sample 
implying the pathogenic mutation had arisen de novo during 
embryogenesis and not been maternally inherited.
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table 1 Table of electrophysiology details
dark adaptometry cone rod
Final dark adapted thresholds after 45 min (log units) −1.4 −1.0
EOG OD OS
Arden Index (%) [>200%] 109 128
Rod ERG Rod ERG
OD OS
  a implicit time (ms) [38.86+/-3.31] 25 24
  b implicit time (ms) [85+/-19.56] 59 58
  a amplitude (μV) [52.29+/-51.21] 62 34
  b amplitude (μV) [250.2+/-143.3] 57 62
Cone ERG
OD OS
  a implicit time (ms) [16.42+/-1.34] 18 17
  b implicit time (ms) [27.75+/-1.73] 36 38
  a amplitude (μV) [38.52+/-23.95] 11 5.0
  b amplitude (μV) [128.7+/-46.9] 16 9.0
Maximal ERG (standard flash)
OD OS
  a implicit time (ms) [16.86+/-3.41] 25 24
  b implicit time (ms) [46.79+/-14.74] 59 58
  a amplitude (μV) [179.8+/-106.1] 62 34
  b amplitude (μV) [333.2+/-201.1] 57 62
PERG P50 OD OS
  Implicit time (ms) [51.6+/-2.8] NMC 59
  Amplitude (μV) [4.1+/-1.7] NMC 1.5
30 Hz ERG OD OS
  Implicit time (ms) [24.33+/-1.97] 36 37
  Amplitude (μV) [106.8+/-32.55] 21 19
*Normal values in square brackets.
EOG, electro-oculogram; ERG , electroretinogram; ms, milliseconds; NMC, no 
measurable components; OD, right ; OS, left; PERG, pattern electroretinogram; μV, 
microvolts.
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Muscle histopathology, biochemistry and single-fibre 
segregation studies
Muscle biopsy analysis showed remarkable mitochondrial histo-
chemical abnormalities characterised by a mosaic pattern of 
cytochrome c oxidase (COX) deficiency affecting ~40% of all 
fibres on both the individual enzyme reaction and the sequen-
tial cytochrome c oxidase-succinate dehydrogenase (COX-SDH) 
reaction (figure 3A) and subsarcolemmal mitochondrial accu-
mulation (ragged-blue fibres affecting ~5% of the total biopsy) 
on the individual SDH reaction (figure 3A), consistent with a 
mitochondrial aetiology. Quadruple oxidative phosphoryla-
tion (OXPHOS) immunofluorescence undertaken according to 
Rocha et al9 confirmed the presence of muscle fibres lacking 
both complex I (NDUFB8) and complex IV (COX-1) expression, 
confirming a multiple respiratory chain defect (figure 3B). Single 
muscle fibre analysis of individual COX-positive and COX-de-
ficient fibres revealed a statistically significant higher mutation 
load in COX-deficient fibres (93.12%±0.26% (n=17 fibres)) 
than in COX-positive fibres (COX-positive fibres: 29.50±8.97 
(n=16 fibres); p<0.0001) confirming pathogenicity of the 
m.8340G>A variant (figure 3C).
Our patient was subsequently referred to a specialist mito-
chondrial clinic for follow-up and counselling with regular 
diabetic screening, cardiology review, ophthalmology review 
and lung function tests to monitor his condition.
dIscussIon
We describe a patient with a rare mtDNA variant associated with 
primarily an ocular phenotype, for which we present data in 
support of pathogenicity. The m.8340G>A variant occurs within 
the TψC stem of the mt-tRNALys molecule (figure 3D) and as 
such results in the disruption of Watson-Crick base pairing.10 
Using a consensus panel of 10 species (figure 3E) to investigate 
evolutionary conservation, the m.8340G>A variant was shown 
to affect a highly conserved residue.11
A revised version of a previously validated scoring system12 
was used to assign a pathogenicity classification to this variant. 
This scoring system uses weighted criteria encompassing 
biochemical and molecular genetic data to assign a pathogenicity 
score (out of a total score of 20) to the variant. The m.8340G>A 
variant is heteroplasmic and has been described previously in 
one other independent report.8 It is shown to affect a highly 
evolutionarily conserved residue and was absent in maternal 
tissue samples. Individual enzyme and sequential COX–SDH 
histochemistry revealed COX-deficient fibres in a skeletal 
muscle biopsy, with mitochondrial immunofluorescence studies 
confirming a multiple respiratory chain defect, consistent with 
a pathogenic mt-tRNA gene variant. Finally, single-fibre anal-
ysis demonstrated a statistically significant segregation of muta-
tion load with biochemical deficiency. The m.8340G>A thus 
scores 15 points with evidence from a gold standard (single-
fibre) investigation, and on this basis we would propose that the 
m.8340G>A is classified as definitely pathogenic.10 12
Although the m.8340G>A variant is listed by PhyloTree as 
occurring in a rare mtDNA haplogroup,13 there is no other 
evidence to support that m.8340G>A may be a neutral poly-
morphism; this variant is absent from all 32 059 mtDNA 
GenBank sequences listed on MitoMAP,3 while our own diag-
nostic laboratory (Newcastle Highly Specialised Service for 
Rare Mitochondrial Disorders) has not detected this variant in 
over 1200 patients who have undergone whole mitochondrial 
genome sequencing (unpublished data). We were able to obtain 
blood, buccal epithelia and urine samples from the patient’s 
mother all of which failed to demonstrate detectable levels of 
the m.8340G>A variant. Allowing for the possibility that the 
mutation may be present in tissues that have not been tested, the 
absence of the m.8340G>A variant in maternal tissues provides 
evidence that the mutation is likely to have arisen sporad-
ically. High levels of heteroplasmy within muscle tissue when 
compared with peripheral tissues, statistically significant segre-
gation of mutation load in single fibres and the absence of the 
rare mtDNA variant in family members are consistent with this 
being a pathogenic, de novo variant.
Our case is also associated with an expanded phenotype 
compared with that described by Jeppesen et al,8 who previously 
reported a single patient with the same m.8340G>A variant, 
but associated with an isolated myopathy. By contrast, the 
patient whose case we report has multisystemic disease including 
a history of epilepsy, migraines, growth hormone deficiency, 
sensorineural deafness and with retinopathy and early-onset 
bilateral cataracts with biopsy confirming muscle involvement. 
Of further interest, the patient investigated by Jeppesen and 
colleagues showed no obvious COX deficiency in muscle, both 
histochemically and biochemically, with an isolated impairment 
of respiratory chain complex I. In contrast, our case showed a 
significant mosaic COX deficiency affecting ~40% of muscle 
fibres with multiple respiratory chain complex impairment 
confirmed following immunohistochemistry. This further illus-
trates the phenotypic variability observed at the level of the 
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Figure 3 Mitochondrial histopathological, biochemical and molecular genetic findings associated with the m.8340G>A MTTK variant. (A) Muscle 
histology and histochemistry in our patient including H&E (i), COX (ii), SDH (iii) and COX-SDH (iv) reveal numerous COX-deficient, ragged-red 
fibres. (b) Quadruple immunofluorescence profile shows loss of both complex I (NDUFBA) and complex IV (COX-1) subunits, confirming a multiple 
mitochondrial respiratory chain disorder. (c) Single-fibre PCR analysis of the m.8340G>A variant demonstrating segregation with a biochemical 
defect in individual COX-deficient muscle fibres. (d) Schematic representation of the mt-RNALys cloverleaf structure, illustrating the position of the 
m.8340G>A variant in the TψC stem. (e) Phylogenetic conservation of the appropriate region of the mt-tRNALys gene sequence showing that the 
m.8340G>A variant affects an evolutionary conserved residue involved in Watson-Crick base pairing.
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biochemical defect, and hence the difficulty in determining a 
phenotype–genotype correlation, across patients with mtDNA 
disease.
Retinopathy in the context of mitochondrial disease is well 
described.14–17 Atypical pigmentary retinal dystrophy predom-
inantly affecting the posterior pole is a feature of many mito-
chondrial diseases (Kearns-Sayre syndrome,18 MIDD19). Further-
more, fundus autofluorescence imaging showed widespread 
speckling and areas of atrophy in the posterior pole, which is 
often described in mitochondrial retinopathies.20 The electro-
physiology is consistent with abnormalities of the photorecep-
tors and retinal pigment epithelium.
Disease-causing mtDNA point mutations present a challenge 
to the clinician both in establishing a diagnosis and further 
management. Phenotypes are heterogeneous and often overlap. 
However, patients presenting with both ophthalmic and systemic 
features should prompt the clinician to consider a mitochondrial 
aetiology as part of the differential diagnosis. If genetic anal-
ysis for common mtDNA mutations does not reveal a mutation, 
whole mitochondrial genome analysis should be performed with 
appropriate pretest counselling. Further referrals to relevant 
specialities may be necessary including cardiology, respiratory, 
neurology, dietician, nephrology and the diabetes screening 
service.
In summary, we report a second case of a rare mitochon-
drial m.8340G>A variant, confirming its pathogenicity on 
the basis of single-fibre segregation studies and its association 
with an expanded clinical phenotype. We recommend that the 
m.8340G>A variant is reclassified as ‘definitely pathogenic’, 
highlighting the need to carry out further, more extensive testing 
in patients in whom a mitochondrial diagnosis is suspected.
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